ABT Abbott Laboratories (ABT) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0000001800
Congress · 3Form 144 · 3
Funds added, last quarter
1,272
13F, latest reported quarter
Conversions, 180 days
2
Codes C/M, not in net · $21.5M priced
What the filings say about ABT
Insiders, 180 days
-$46.7M net sold
1 buyer · 3 sellers · 0% of sales under a 10b5-1 plan
Congress, 1 year
3 bought · 9 sold
Latest: purchase, 2026-09-18
Planned sales (Form 144), 90 days
$46.8M
3 notices
Abbott Laboratories insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, ABBOTT LABORATORIES insiders sold a net $46.7M of stock across 137 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Mar 2, 2026.
- The trade is 0.1% of the 24,549 shares held after it.
- 2 other insiders sold within 30 days.
- 1,272 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: VICE PRESIDENT AND CONTROLLER MCCOY JOHN A. JR. sold about $3.0K of ABT on Sep 2, 2026; 2 other insiders sold within 30 days and 1,272 funds added in the latest 13F quarter.Context
- 5 earlier Form 4 trades (code P or S) here by this insider (1 buy, 4 sales), the last on Jan 23, 2026.
- The trade is 44.9% of the 486,758 shares held after it.
- 2 other insiders sold within 30 days.
- 1,272 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHAIRMAN AND CEO Ford Robert B sold about $25.3M of ABT on Aug 25, 2026, the largest insider sale at the company since 2025; 2 other insiders sold within 30 days and 1,272 funds added in the latest 13F quarter.Context
- 5 earlier Form 4 trades (code P or S) here by this insider (1 buy, 4 sales), the last on Jan 23, 2026.
- The trade is 58.8% of the 306,461 shares held after it.
- 2 other insiders sold within 30 days.
- 1,272 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHAIRMAN AND CEO Ford Robert B sold about $20.9M of ABT on Aug 25, 2026, the largest insider sale at the company since 2025; 2 other insiders sold within 30 days and 1,272 funds added in the latest 13F quarter.Context
- 9 earlier Form 4 trades (code P or S) here by this insider (9 sales), the last on Mar 2, 2026.
- The trade is 8.3% of the 70,724 shares held after it.
- 2 other insiders sold within 30 days.
- 1,272 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EXECUTIVE VICE PRESIDENT Morrone Louis H. sold about $642.5K of ABT on Aug 11, 2026, the largest insider sale at the company since 2025; 2 other insiders sold within 30 days and 1,272 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 8.6% of the 23,319 shares held after it.
- 2 other insiders bought within 30 days.
- 1,272 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Stratton John G bought about $173.6K of ABT on May 7, 2026; 2 other insiders bought within 30 days and 1,272 funds added in the latest 13F quarter.137 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$46.7M over 180 days
-$46.9M over 90 days
below 94% of Pharma & Biotech
Congress
3 members bought in the last year
more than 90% of Pharma & Biotech
Funds
1,272 funds bought in last quarter
more than 99% of Pharma & Biotech
Revenue
+5.7% year over year
more than 54% of Pharma & Biotech
Margin
14.7% net margin
more than 85% of Pharma & Biotech
Buybacks
$180.0M repurchased, FY to 2026-03-31
more than 76% of Pharma & Biotech
Short interest
0.8% of the float short (float per yahoo 2026-10-26) · 1.5 days to cover · settled 2026-09-30
below 75% of Pharma & Biotech
What changed in the last 30 days
Oct 12Rep. Gilbert Cisneros sold $1.0K to $15K, disclosed 24 days after the trade
Why it matters
House members report a bracket, not an exact amount, and have 45 days to do it; the trade is weeks old when it becomes public.
Watch ABT
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-16.5%12M
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns ABT: institutional holders (13F)
13F holdings, latest reported quarter
152,563,476 sh
$13.8B
113,750,994 sh
$10.3B
80,926,234 sh
$7.3B
59,674,507 sh
$5.4B
59,674,507 sh
$5.4B
Congress trades in ABT
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Bought 2026-09-18 · disclosed 24 days later
$1,001 - $15,000
Sold 2026-07-30 · disclosed 15 days later
$1,001 - $15,000
Sold 2026-07-17 · disclosed 26 days later
$1,001 - $15,000
Sold 2026-07-14 · disclosed 35 days later
$15,001 - $50,000
Sold 2026-07-08 · disclosed 4 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
ABT planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
John A. McCoy, Jr.
Filed 2026-09-02
$3.0K
Robert B. Ford
Filed 2026-08-25
$46.2M
Louis H. Morrone
Filed 2026-08-11
$642.5K
ABT mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
iShares U.S. Medical Devices ETF
$512.0M position · as of 2026-06-30
16.9%
DIAMOND HILL SELECT FUND
$34.2M position · as of 2026-06-30
6.3%
DIAMOND HILL LARGE CAP CONCENTRATED ETF
$5.2M position · as of 2026-06-30
5.9%
Invesco Pharmaceuticals ETF
$26.8M position · as of 2026-07-31
5.7%
DIAMOND HILL LARGE CAP FUND
$125.8M position · as of 2026-06-30
4.4%
Longleaf Partners Fund
$46.0M position · as of 2026-06-30
4.3%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Government contracts
Award ceilings over the contract's life, subsidiaries included.
Not annual revenue (USASpending.gov).
Department Of Health And Human Services
ABBOTT: TO CONDUCT CLINICAL TRAINING AND VALIDATION STUDIES TO SUPPORT A FUTURE FDA MARKETING APPLIC · 2022-09-21
$65.5M
Department Of Health And Human Services
AGENCY WIDE IDIQ CONTRACT TO PROVIDE LABORATORY ANALYZERS, TESTING KITS/REAGENTS, ASSOCIATED PERIPHE · 2022-09-23
$55.1M
Department Of Veterans Affairs
VISN 9 CHEMISTRY AUTOMATION COST PER RESULTS REPORTABLE · 2024-04-01
$11.4M
Department Of Veterans Affairs
CHEMICAL ANALYZER · 2022-02-11
$10.1M
Department Of Veterans Affairs
COST PER REPORTABLE RESULT VA PUGET SOUND HEALTH CARE SYSTEM · 2020-12-01
$5.7M
Department Of Veterans Affairs
ABBOTT ALINITY M REAGENTS AND CONSUMABLES · 2024-04-01
$5.5M
Federal awards ≥ $25M in the last 90 days, matched via the SAM.gov parent registry
Corporate PAC
The company's PAC: committee totals only, never individual donors (FEC).
Abbott Laboratories Employee Political Action Committee
Cycle 2026 · $1,651K spent
$1.5M
Federal Election Commission, matched by the PAC's connected organisation
Executive pay vs shareholder return · Robert B. Ford
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$24.2M
$26.8M
$7.5M
+25%
+48%
2024
$22.8M
$24.8M
$7.4M
+42%
+47%
2023
$23.3M
$20.5M
$6.2M
+36%
+43%
2022
$21.7M
$8.0M
$7.4M
+33%
+40%
2021
$24.9M
$43.3M
$9.3M
+67%
+43%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $46.7M sold by insiders over 180 days, 1,272 funds added last quarter, 3 House member(s) bought in 12 months, disclosed weeks after the trade, $46.8M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
ABT financials
Revenue growth
+5.7%
XBRL, annual
Net margin
14.7%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$45.1B
four quarters, 2025-04-01 to 2026-03-31
Revenue, TTM ABT
| FY Dec 2025 | $44.3B |
| FY Dec 2024 | $42.0B |
| FY Dec 2023 | $40.1B |
| FY Dec 2022 | $43.7B |
| FY Dec 2021 | $43.1B |
| Mar 2026 | $11.2B |
| Dec 2025 | $11.5B |
| Sep 2025 | $11.4B |
| Jun 2025 | $11.1B |
| Mar 2025 | $10.4B |
| Dec 2024 | $11.0B |
| Sep 2024 | $10.6B |
| Jun 2024 | $10.4B |
At each fiscal year end
Single quarter
Net margin, TTM
+13.9%
net income over revenue, 2025-04-01 to 2026-03-31
Net margin, TTM ABT
| FY Dec 2025 | +14.7% |
| FY Dec 2024 | +31.9% |
| FY Dec 2023 | +14.3% |
| FY Dec 2022 | +15.9% |
| FY Dec 2021 | +16.4% |
| Mar 2026 | +9.6% |
| Dec 2025 | +15.5% |
| Sep 2025 | +14.5% |
| Jun 2025 | +16.0% |
| Mar 2025 | +12.8% |
| Dec 2024 | +84.1% |
| Sep 2024 | +15.5% |
| Jun 2024 | +12.5% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$7.4B
operating cash flow minus capex, 2025-04-01 to 2026-03-31
Free cash flow, TTM ABT
| FY Dec 2025 | $7.4B |
| FY Dec 2024 | $6.4B |
| FY Dec 2023 | $5.1B |
| FY Dec 2022 | $7.8B |
| FY Dec 2021 | $8.6B |
| Mar 2026 | $916.0M |
| Dec 2025 | $2.6B |
| Sep 2025 | $2.3B |
| Jun 2025 | $1.5B |
| Mar 2025 | $933.0M |
| Dec 2024 | $2.1B |
| Sep 2024 | $2.1B |
| Jun 2024 | $1.4B |
At each fiscal year end
Single quarter
Debt to equity
0.65x
long-term 2026-03-31 plus current 2026-03-31; equity 2026-03-31
Debt to equity ABT
| FY Dec 2025 | 0.25x |
| FY Dec 2024 | 0.30x |
| FY Dec 2023 | 0.38x |
| FY Dec 2022 | 0.46x |
| FY Dec 2021 | 0.50x |
| Mar 2026 | 0.65x |
| Dec 2025 | 0.25x |
| Sep 2025 | 0.25x |
| Jun 2025 | 0.27x |
| Mar 2025 | 0.27x |
| Dec 2024 | 0.30x |
| Sep 2024 | 0.38x |
| Jun 2024 | 0.38x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.28x
TTM operating cash flow over long-term 2026-03-31 plus current 2026-03-31
Cash flow to debt ABT
| FY Dec 2025 | 0.74x |
| FY Dec 2024 | 0.61x |
| FY Dec 2023 | 0.49x |
| FY Dec 2022 | 0.57x |
| FY Dec 2021 | 0.58x |
| Mar 2026 | 0.28x |
| Dec 2025 | 0.74x |
| Sep 2025 | 0.70x |
| Jun 2025 | 0.67x |
| Mar 2025 | 0.68x |
| Dec 2024 | 0.61x |
| Sep 2024 | 0.58x |
| Jun 2024 | 0.54x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+12.4%
TTM net income over average of 2025-03-31 and 2026-03-31
Return on equity ABT
| FY Dec 2025 | +13.1% |
| FY Dec 2024 | +31.1% |
| FY Dec 2023 | +15.2% |
| FY Dec 2022 | +19.1% |
| FY Dec 2021 | +20.6% |
| Mar 2026 | +12.4% |
| Dec 2025 | +13.1% |
| Sep 2025 | +30.8% |
| Jun 2025 | +31.1% |
| Mar 2025 | +30.8% |
| Dec 2024 | +31.1% |
| Sep 2024 | +14.9% |
| Jun 2024 | +14.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+6.5%
TTM net income over average of 2025-03-31 and 2026-03-31
Return on assets ABT
| FY Dec 2025 | +7.8% |
| FY Dec 2024 | +17.3% |
| FY Dec 2023 | +7.8% |
| FY Dec 2022 | +9.3% |
| FY Dec 2021 | +9.6% |
| Mar 2026 | +6.5% |
| Dec 2025 | +7.8% |
| Sep 2025 | +17.6% |
| Jun 2025 | +17.8% |
| Mar 2025 | +17.5% |
| Dec 2024 | +17.3% |
| Sep 2024 | +7.9% |
| Jun 2024 | +7.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+7.6%
operating income after a 22.9% effective tax rate, over long-term 2026-03-31 plus current 2026-03-31 plus average of 2025-03-31 and 2026-03-31 minus cash
Return on invested capital ABT
| FY Dec 2025 | +11.3% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | +12.7% |
| FY Dec 2022 | +16.2% |
| FY Dec 2021 | +16.5% |
| Mar 2026 | +7.6% |
| Dec 2025 | +11.3% |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | +12.3% |
| Jun 2024 | +12.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+9.6%
operating income (EBIT proxy) over average of 2025-03-31 and 2026-03-31 minus current liabilities
Return on capital employed ABT
| FY Dec 2025 | +11.7% |
| FY Dec 2024 | +10.8% |
| FY Dec 2023 | +10.9% |
| FY Dec 2022 | +13.8% |
| FY Dec 2021 | +13.7% |
| Mar 2026 | +9.6% |
| Dec 2025 | +11.7% |
| Sep 2025 | +12.0% |
| Jun 2025 | +11.6% |
| Mar 2025 | +11.2% |
| Dec 2024 | +10.8% |
| Sep 2024 | +11.3% |
| Jun 2024 | +11.0% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
29.30x
close 2026-10-26 over four quarters of diluted EPS, 2025-04-01 to 2026-03-31
P/E, trailing ABT
| FY Dec 2025 | 33.59x |
| FY Dec 2024 | 14.80x |
| FY Dec 2023 | 33.76x |
| FY Dec 2022 | 28.08x |
| FY Dec 2021 | 35.72x |
| Mar 2026 | 28.68x |
| Dec 2025 | 33.59x |
| Sep 2025 | 16.81x |
| Jun 2025 | 17.07x |
| Mar 2025 | 17.23x |
| Dec 2024 | 14.80x |
| Sep 2024 | 34.65x |
| Jun 2024 | 32.78x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$209.9B
market value at close 2026-10-26 on 2026-03-31 shares, plus long-term 2026-03-31 plus current 2026-03-31, minus cash 2026-03-31
Enterprise value ABT
| FY Dec 2025 | $222.3B |
| FY Dec 2024 | $202.7B |
| FY Dec 2023 | $198.9B |
| FY Dec 2022 | $198.3B |
| FY Dec 2021 | $257.1B |
| Mar 2026 | $206.1B |
| Dec 2025 | $222.3B |
| Sep 2025 | $238.3B |
| Jun 2025 | $243.2B |
| Mar 2025 | $237.5B |
| Dec 2024 | $202.7B |
| Sep 2024 | $205.2B |
| Jun 2024 | $188.6B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+4.0%
TTM free cash flow over market value at close 2026-10-26
FCF yield ABT
| FY Dec 2025 | +3.4% |
| FY Dec 2024 | +3.2% |
| FY Dec 2023 | +2.6% |
| FY Dec 2022 | +4.1% |
| FY Dec 2021 | +3.5% |
| Mar 2026 | +4.1% |
| Dec 2025 | +3.4% |
| Sep 2025 | +3.0% |
| Jun 2025 | +2.9% |
| Mar 2025 | +2.9% |
| Dec 2024 | +3.2% |
| Sep 2024 | +3.3% |
| Jun 2024 | +3.1% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing EPS growth -54%, PEG needs growth
PEG, trailing ABT
| FY Dec 2025 | n/a |
| FY Dec 2024 | 0.11x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 0.62x |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | 0.12x |
| Jun 2025 | 0.11x |
| Mar 2025 | 0.12x |
| Dec 2024 | 0.11x |
| Sep 2024 | 2.91x |
| Jun 2024 | 4.00x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $44.3B | $42.0B | $40.1B | $43.7B |
| Operating income | $8.1B | $6.8B | $6.5B | $8.4B |
| Net income | $6.5B | $13.4B | $5.7B | $6.9B |
| EPS (diluted) | 3.72 | 7.64 | 3.26 | 3.91 |
| Operating cash flow | $9.6B | $8.6B | $7.3B | $9.6B |
| Cash | $8.5B | $7.6B | $6.9B | $9.9B |
| Long-term debt | $9.9B | $12.6B | $13.6B | $14.5B |
| Buybacks | $893.0M | $1.3B | $1.2B | $3.8B |
| Dividends paid | $4.1B | $3.8B | $3.6B | $3.3B |
SEC XBRL, fiscal years, as known on 2026-10-27
ABT Stock Sonar score 6/7 axes
Find similar shapesCompareABT ranks highest on profitability (72nd percentile) and institutional and government (65th), and lowest on insider conviction (30th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
ABT filings, in plain words
Are Abbott Laboratories insiders buying or selling ABT?
In the 180 days to 2026-10-27, Abbott Laboratories insiders were net sellers, a net $46.7M: $173.6K of purchases and $46.9M of sales reported on Form 4, by 1 buyer and 3 sellers.
Have members of Congress traded ABT?
Yes. In the year to 2026-10-27, 3 House members disclosed buying ABT and 9 House members disclosed selling it; the latest on record is a purchase by Gilbert Cisneros dated 2026-09-18.
Are there planned insider sales of ABT?
Yes. 3 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $46.8M of stock; the latest, by John A. McCoy, Jr., was filed 2026-09-02.
Read the full summary
In the 180 days to 2026-10-27, Abbott Laboratories insiders were net sellers of ABT, a net $46.7M across purchases and sales reported on Form 4 by 1 buyer and 3 sellers. Sales outweighed purchases more than tenfold by value. None of the 4 insider sales was flagged as made under a Rule 10b5-1 plan. In the year to 2026-10-27, 3 members of Congress disclosed buying ABT and 9 members disclosed selling it; the latest on record is a purchase by Gilbert Cisneros dated 2026-09-18. Insiders filed 3 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $46.8M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
